Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls

Simple Summary Genomic profiling of non-small cell lung cancer (NSCLC) patients offers the possibility of therapeutic intervention with target-based agents. The analysis of circulating free DNA (cfDNA) through next generation sequencing (NGS) technologies is emerging as a powerful tool to assess the whole tumor molecular landscape of NSCLC patients and characterize spatial and temporal tumor heterogeneity. Moreover, cfDNA NGS testing allows the monitoring of therapy response and the early identification of resistance mechanisms. In this review, we describe the importance of implementation of cfDNA NGS testing in routine clinical practice to improve targeted diagnostic procedures and personalized therapies in NSCLC patients. Abstract Lung cancer (LC) is the main cause of death for cancer worldwide and non-small cell lung cancer (NSCLC) represents the most common histology. The discovery of genomic alterations in driver genes that offer the possibility of therapeutic intervention has completely changed the approach to the diagnosis and therapy of advanced NSCLC patients, and tumor molecular profiling has become mandatory for the choice of the most appropriate therapeutic strategy. However, in approximately 30% of NSCLC patients tumor tissue is inadequate for biomarker analysis. The development of highly sensitive next generation sequencing (NGS) technologies for the analysis of circulating cell-free DNA (cfDNA) is emerging as a valuable alternative to assess tumor molecular landscape in case of tissue unavailability. Additionally, cfDNA NGS testing can better recapitulate NSCLC heterogeneity as compared with tissue testing. In this review we describe the main advantages and limits of using NGS-based cfDNA analysis to guide the therapeutic decision-making process in advanced NSCLC patients, to monitor the response to therapy and to identify mechanisms of resistance early. Therefore, we provide evidence that the implementation of cfDNA NGS testing in clinical research and in the clinical practice can significantly improve precision medicine approaches in patients with advanced NSCLC.

[1]  H. Groen,et al.  Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[2]  A. Drilon,et al.  Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[3]  N. Leighl,et al.  Mechanisms of osimertinib resistance and emerging treatment options. , 2020, Lung cancer.

[4]  C. Lázaro,et al.  High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome , 2020 .

[5]  D. Planchard,et al.  Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay , 2020, PloS one.

[6]  Jie Yang,et al.  Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. , 2020, The New England journal of medicine.

[7]  S. Mortimer,et al.  Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases , 2020, Cancer.

[8]  J. Zhao,et al.  Targeting HER2 Alterations in Non-Small-Cell Lung Cancer: A Comprehensive Review. , 2020, JCO precision oncology.

[9]  Yanxi Han,et al.  Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[10]  T. Druley,et al.  The evolutionary dynamics and fitness landscape of clonal hematopoiesis , 2020, Science.

[11]  V. Calvo,et al.  Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report , 2020, Translational lung cancer research.

[12]  N. Normanno,et al.  Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications , 2020, Translational lung cancer research.

[13]  R. Soo,et al.  Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies , 2020, Therapeutic advances in medical oncology.

[14]  I. Boukovinas,et al.  Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients , 2019, PloS one.

[15]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[16]  Yong He,et al.  Serial ultra‐deep sequencing of circulating tumor DNA reveals the clonal evolution in non‐small cell lung cancer patients treated with anti‐PD1 immunotherapy , 2019, Cancer medicine.

[17]  David R. Jones,et al.  High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants , 2019, Nature Medicine.

[18]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[19]  Ying Cheng,et al.  Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer , 2019, Clinical Cancer Research.

[20]  L. Bubendorf,et al.  Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study , 2019, Cell Death & Disease.

[21]  C. Smart,et al.  Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients. , 2019, Lung cancer.

[22]  N. Murugaesu,et al.  Clinical Analysis of Whole Genome Sequencing in Cancer Patients , 2019, Current Genetic Medicine Reports.

[23]  L. Sequist,et al.  Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[24]  A. Shaw,et al.  Molecular Analysis of Plasma From Patients With ROS1‐Positive NSCLC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  S. Zupo,et al.  Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients , 2019, Molecular Medicine.

[26]  Jing Wang,et al.  Whole Exome Sequencing of Cell-Free DNA for Early Lung Cancer: A Pilot Study to Differentiate Benign From Malignant CT-Detected Pulmonary Lesions , 2019, Front. Oncol..

[27]  V. Papadimitrakopoulou,et al.  Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer , 2019, Clinical Cancer Research.

[28]  Tristan J. Lubinski,et al.  Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance. , 2019, JCO precision oncology.

[29]  V. Plagnol,et al.  Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. , 2019, Lung cancer.

[30]  G. Botti,et al.  The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients , 2019, Cancers.

[31]  R. Herbst,et al.  Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes , 2019, Clinical Cancer Research.

[32]  Sharyn I. Katz,et al.  Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer , 2019, JAMA oncology.

[33]  S. Leroy,et al.  Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. , 2019, Journal of thoracic disease.

[34]  N. Normanno,et al.  The role of circulating free DNA in the management of NSCLC , 2018, Expert review of anticancer therapy.

[35]  F. Fulfaro,et al.  Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis , 2018, Scientific Reports.

[36]  N. Normanno,et al.  Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. , 2018, Translational lung cancer research.

[37]  Xue Wu,et al.  Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. , 2018, Lung cancer.

[38]  R. Rosell,et al.  Therapeutic approaches for T790M mutation positive non-small-cell lung cancer , 2018, Expert review of anticancer therapy.

[39]  E. Helman,et al.  Cell‐Free DNA Next‐Generation Sequencing Prediction of Response and Resistance to Third‐Generation EGFR Inhibitor , 2018, Clinical lung cancer.

[40]  Jacob Silterra,et al.  Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.

[41]  N. Girard,et al.  Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy , 2018, Nature Reviews Clinical Oncology.

[42]  N. Rosenfeld,et al.  Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer , 2018, EMBO molecular medicine.

[43]  Hongbing Shen,et al.  Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients , 2018, Nature Communications.

[44]  Y. Huang,et al.  Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[45]  C. Paweletz,et al.  Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies , 2018, Clinical Cancer Research.

[46]  C. Paweletz,et al.  Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Alison S. Devonshire,et al.  Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA , 2018, PloS one.

[48]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[49]  J. Shih,et al.  Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer , 2018, Molecular Cancer.

[50]  Abhijit A. Patel,et al.  Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA , 2018, Clinical Cancer Research.

[51]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[52]  Yih-Leong Chang,et al.  Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. , 2017, The Lancet. Respiratory medicine.

[53]  Ash A. Alizadeh,et al.  Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. , 2017, Cancer discovery.

[54]  Maximilian Diehn,et al.  Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers , 2017, Nature Genetics.

[55]  B. Halmos,et al.  Circulating Tumor DNA in Non-Small-Cell Lung Cancer: A Primer for the Clinician. , 2017, JCO precision oncology.

[56]  Sam Angiuoli,et al.  Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[57]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[58]  R. Kurzrock,et al.  Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma , 2017, Clinical Cancer Research.

[59]  Nicolai J. Birkbak,et al.  Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[60]  R. Chiari,et al.  Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence , 2017, Medical Oncology.

[61]  J. Mazières,et al.  Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma , 2017, Oncotarget.

[62]  N. Rosenfeld,et al.  Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  A. Bardelli,et al.  Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.

[64]  N. Normanno,et al.  Targeting the EGFR T790M mutation in non-small-cell lung cancer , 2017, Expert opinion on therapeutic targets.

[65]  N. Normanno,et al.  Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer , 2016, Oncotarget.

[66]  M. Erlander,et al.  A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[67]  G. Botti,et al.  Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma , 2016, Oncotarget.

[68]  Ash A. Alizadeh,et al.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.

[69]  Ash A. Alizadeh,et al.  Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.

[70]  Jian Zhang,et al.  ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance , 2016, Oncotarget.

[71]  A. Borczuk,et al.  Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. , 2016, Archives of pathology & laboratory medicine.

[72]  J Carl Barrett,et al.  EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. , 2015, Lung cancer.

[73]  Hanlee P. Ji,et al.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.

[74]  Y. Yatabe,et al.  Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[75]  B. Kermani,et al.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[76]  R. Strausberg,et al.  Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[77]  Eric Samorodnitsky,et al.  Evaluation of Hybridization Capture Versus Amplicon‐Based Methods for Whole‐Exome Sequencing , 2015, Human mutation.

[78]  R. Franco,et al.  EGFR mutations in lung cancer: from tissue testing to liquid biopsy. , 2015, Future oncology.

[79]  K. Kiura,et al.  Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer , 2015, Cancers.

[80]  Nitzan Rosenfeld,et al.  Circulating tumor-derived DNA is shorter than somatic DNA in plasma , 2015, Proceedings of the National Academy of Sciences.

[81]  Dong-Wan Kim,et al.  Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[82]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[83]  K. Kinzler,et al.  Abstract 5606: Detection of circulating tumor DNA in early and late stage human malignancies , 2014 .

[84]  R. Rosell,et al.  Signaling pathways modulating dependence of lung cancer on mutant epidermal growth factor receptor and mechanisms of intrinsic and acquired resistance to tyrosine kinase inhibitors. , 2014, Current pharmaceutical design.

[85]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[87]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[89]  A. Rossi,et al.  Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? , 2013, Cancer treatment reviews.

[90]  N. Rosenfeld,et al.  Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.

[91]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[92]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[93]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[94]  N. Rosenfeld,et al.  Are liquid biopsies a surrogate for tissue EGFR testing? , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[95]  L. Paz-Ares,et al.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  Jeffrey W. Clark,et al.  Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .